• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌病理缓解的辅助化疗分析。

Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer.

机构信息

Department of Pathology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District, 110042 Shenyang City, Liaoning Province, China.

Department of Pathology, College of Basic Medical Sciences, China Medical University, No. 77 Puhe Road, 110122 Shenyang City, Liaoning Province, China.

出版信息

Comput Math Methods Med. 2021 Nov 15;2021:5440154. doi: 10.1155/2021/5440154. eCollection 2021.

DOI:10.1155/2021/5440154
PMID:34819989
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8608491/
Abstract

With the continuous development of the concept of diagnosis and treatment, the current industry's treatment model has developed into a multidisciplinary comprehensive treatment. That is, in view of the pathological characteristics and clinical stages of breast cancer, corresponding methods such as surgery, chemotherapy, endocrine therapy, radiotherapy, and biological targeted therapy are adopted to provide comprehensive treatment of patients with multiple disciplines. This paper combines experimental research to research and analyze the degree of pathological remission of breast cancer by adjuvant chemotherapy and combines investigation and analysis and group trials to study and explore the effect of adjuvant chemotherapy. Moreover, this paper fully considers the patient's response to neoadjuvant chemotherapy and compares the changes in tumor cell abundance before and after chemotherapy to observe the response of the patient's primary tumor to chemotherapy at a microscopic level. Therefore, this study has made a relatively objective and accurate evaluation of the chemotherapy efficacy of tumor tissues, which can provide a reference for subsequent related research.

摘要

随着诊疗理念的不断发展,目前业界的治疗模式已经发展成多学科综合治疗。即针对乳腺癌的病理特点和临床分期,采用手术、化疗、内分泌治疗、放疗、生物靶向治疗等相应的方法,为患者提供多学科的综合治疗。本文结合实验研究,研究分析辅助化疗使乳腺癌病理缓解的程度,并结合调查分析和分组试验,研究探讨辅助化疗的效果。此外,本文充分考虑了患者对新辅助化疗的反应,并比较了化疗前后肿瘤细胞丰度的变化,从微观层面观察患者原发肿瘤对化疗的反应。因此,本研究对肿瘤组织的化疗疗效进行了相对客观和准确的评价,可为后续相关研究提供参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/2e83f356fbaa/CMMM2021-5440154.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/e61db0d87dd8/CMMM2021-5440154.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/73b0ae80d078/CMMM2021-5440154.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/d324cbf10e40/CMMM2021-5440154.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/677db56cc6ec/CMMM2021-5440154.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/70fac91166e8/CMMM2021-5440154.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/d8d43bcb10af/CMMM2021-5440154.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/b7d34fc22dd5/CMMM2021-5440154.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/2e83f356fbaa/CMMM2021-5440154.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/e61db0d87dd8/CMMM2021-5440154.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/73b0ae80d078/CMMM2021-5440154.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/d324cbf10e40/CMMM2021-5440154.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/677db56cc6ec/CMMM2021-5440154.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/70fac91166e8/CMMM2021-5440154.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/d8d43bcb10af/CMMM2021-5440154.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/b7d34fc22dd5/CMMM2021-5440154.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12a9/8608491/2e83f356fbaa/CMMM2021-5440154.008.jpg

相似文献

1
Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer.乳腺癌病理缓解的辅助化疗分析。
Comput Math Methods Med. 2021 Nov 15;2021:5440154. doi: 10.1155/2021/5440154. eCollection 2021.
2
[Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].含吡柔比星方案作为原发性乳腺癌新辅助及辅助化疗的疗效分析
Zhonghua Zhong Liu Za Zhi. 2012 Feb;34(2):143-6. doi: 10.3760/cma.j.issn.0253-3766.2012.02.014.
3
[Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].[FEC和TEC方案新辅助化疗对乳腺癌的疗效]
Ai Zheng. 2009 Mar;28(3):292-6.
4
[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].卡铂联合紫杉醇新辅助治疗局部晚期三阴性乳腺癌的II期临床试验
Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011.
5
Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.新辅助化疗与辅助化疗相比,仅在完全病理缓解的三阴性乳腺癌患者中与生存改善相关。
Ann Surg Oncol. 2012 Jan;19(1):253-8. doi: 10.1245/s10434-011-1877-y. Epub 2011 Jul 2.
6
Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy.磁共振成像在预测三阴性乳腺癌新辅助化疗后的病理反应中的应用
J Clin Oncol. 2007 Dec 10;25(35):5667-9. doi: 10.1200/JCO.2007.14.6134.
7
The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.发展中国家乳腺癌新辅助化疗的实际情况:来自印度一家三级癌症中心的 80 例乳腺癌报告。
J Cancer Res Clin Oncol. 2014 Oct;140(10):1777-82. doi: 10.1007/s00432-014-1724-1. Epub 2014 Jun 4.
8
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.种族差异对乳腺癌新辅助化疗的应用和结局的影响:来自国家癌症数据库的结果。
J Clin Oncol. 2015 Dec 20;33(36):4267-76. doi: 10.1200/JCO.2015.63.7801. Epub 2015 Nov 23.
9
Ten-year outcome after combined modality therapy for inflammatory breast cancer.炎性乳腺癌综合治疗后的十年预后
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1200-8. doi: 10.1016/s0360-3016(02)04201-3.
10
Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.新辅助化疗后病理完全缓解的乳腺癌患者早期脑转移。
Anticancer Res. 2013 Nov;33(11):5119-21.

引用本文的文献

1
Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes.浸润性乳腺癌新辅助化疗的反应可通过 CD4+、CD8+ 和 FOXP3+肿瘤浸润淋巴细胞预测。
Asian Pac J Cancer Prev. 2024 May 1;25(5):1607-1613. doi: 10.31557/APJCP.2024.25.5.1607.
2
Retracted: Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer.撤稿:辅助化疗对乳腺癌病理缓解的分析。
Comput Math Methods Med. 2022 Dec 13;2022:9898129. doi: 10.1155/2022/9898129. eCollection 2022.

本文引用的文献

1
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.乳腺癌的新辅助化疗、内分泌治疗和靶向治疗:ASCO 指南。
J Clin Oncol. 2021 May 1;39(13):1485-1505. doi: 10.1200/JCO.20.03399. Epub 2021 Jan 28.
2
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.度伐鲁单抗对比转移性乳腺癌的维持化疗:随机 II 期 SAFIR02-BREAST IMMUNO 试验。
Nat Med. 2021 Feb;27(2):250-255. doi: 10.1038/s41591-020-01189-2. Epub 2021 Jan 18.
3
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌(KEYNOTE-355):一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
4
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.早期三阴性乳腺癌患者新辅助阿替利珠单抗联合序贯纳武利尤单抗和基于蒽环类的化疗与安慰剂和化疗相比:一项随机、双盲、III 期试验(IMpassion031)。
Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20.
5
Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer.工程化巨噬细胞衍生的外泌体用于三阴性乳腺癌的靶向化疗
Nanoscale. 2020 May 21;12(19):10854-10862. doi: 10.1039/d0nr00523a.
6
Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival.高风险乳腺癌化疗前后的体力活动与生存的关系。
J Natl Cancer Inst. 2021 Jan 4;113(1):54-63. doi: 10.1093/jnci/djaa046.
7
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.帕博利珠单抗联合新辅助化疗对早期乳腺癌患者病理完全缓解的影响:正在进行的 2 期适应性随机 I-SPY2 试验分析。
JAMA Oncol. 2020 May 1;6(5):676-684. doi: 10.1001/jamaoncol.2019.6650.
8
Effect of Surgery Type on Time to Adjuvant Chemotherapy and Impact of Delay on Breast Cancer Survival: A National Cancer Database Analysis.手术类型对辅助化疗时间的影响及延迟对乳腺癌生存的影响:国家癌症数据库分析。
Ann Surg Oncol. 2019 Oct;26(10):3240-3249. doi: 10.1245/s10434-019-07566-7. Epub 2019 Jul 22.
9
Chemotherapy-Induced Extracellular Vesicle miRNAs Promote Breast Cancer Stemness by Targeting .化疗诱导的细胞外囊泡 miRNAs 通过靶向. 促进乳腺癌干细胞特性
Cancer Res. 2019 Jul 15;79(14):3608-3621. doi: 10.1158/0008-5472.CAN-18-4055. Epub 2019 May 22.
10
Radiomics of Multiparametric MRI for Pretreatment Prediction of Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter Study.多参数 MRI 放射组学预测乳腺癌新辅助化疗病理完全缓解的价值:一项多中心研究。
Clin Cancer Res. 2019 Jun 15;25(12):3538-3547. doi: 10.1158/1078-0432.CCR-18-3190. Epub 2019 Mar 6.